What Makes Recursion Pharmaceuticals (RXRX) So Attractive [Yahoo! Finance]
Recursion Pharmaceuticals, Inc. - Class A (RXRX)
Company Research
Source: Yahoo! Finance
Recursion Pharmaceuticals Inc. (NASDAQ: RXRX ) is one of the 11 most popular AI penny stocks to buy now On February 25, Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) reported Q4 revenue of $35.5 million compared to the consensus estimates of $24.6 million. The company's cash, cash equivalents, and restricted cash balance totaled $753.9 million as of December 31, compared with $603 million as of the end of last year. The company's cash runway is expected to extend into early 2028 based on current operating plans without the need for additional financing. CEO & President Najat Khan said the company has now reached an inflection point where the organization is no longer just proving the role of AI in drug discovery but is now proving the clinical proof and long-term value of an AI-native operating system. The fact that this is the first AI-enabled clinical proof of concept in FAP, along with the fact that this is the fifth Sanofi program milestone, shows the maturity of the model.
Show less
Read more
Impact Snapshot
Event Time:
RXRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RXRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RXRX alerts
High impacting Recursion Pharmaceuticals, Inc. - Class A news events
Weekly update
A roundup of the hottest topics
RXRX
News
- Jim Cramer on Recursion Pharmaceuticals: “It's a Let Down, Big Let Down” [Yahoo! Finance]Yahoo! Finance
- Is Recursion Pharmaceuticals (RXRX) Pricing Reflect Recent 1-Year Share Slump Accurately [Yahoo! Finance]Yahoo! Finance
- Recursion's First AI Clinical Proof Links Pipeline Progress With Valuation Gap [Yahoo! Finance]Yahoo! Finance
- Can This AI Stock Bounce Back in 2026? [Yahoo! Finance]Yahoo! Finance
- BoFA Lowers PT on Recursion Pharmaceuticals (RXRX), Keeps a Hold Rating [Yahoo! Finance]Yahoo! Finance
RXRX
Earnings
- 2/25/26 - Beat
RXRX
Sec Filings
- 3/17/26 - Form 144
- 3/11/26 - Form 4
- 3/11/26 - Form 4
- RXRX's page on the SEC website